This is a 12-week study to determine the effect on glucose and lipids, safety, and
tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo
in patients with type 2 diabetes. Improvement in dyslipidemia will be evaluated. The study
comprises a 2-week screening period, 4-week placebo run-in, a 12-week randomized, double
blind, parallel group, multi-center, placebo-controlled treatment period, and a 3-week
follow-up.